{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T21:59:27Z","timestamp":1757627967202,"version":"3.44.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-11334-2","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T03:31:13Z","timestamp":1756870273000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["No changes in weight, body composition or metabolic parameters after the switch to dolutegravir and lamivudine compared to continued treatment with dolutegravir, abacavir and lamivudine for virologically suppressed HIV infection (The AVERTAS trial)"],"prefix":"10.1186","volume":"25","author":[{"given":"Karen Brorup","family":"Heje","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magnus S\u00f8ltoft","family":"Lindhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Meddis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gitte","family":"Kronborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Weis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Mette","family":"Lebech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole","family":"Kirk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jannik","family":"Helweg-Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten","family":"Helms","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian Philip","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann-Brit Eg","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f8ren","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartwig Roman","family":"Siebner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens Dahlgaard","family":"Hove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Gerstoft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Benfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"11334_CR1","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1093\/cid\/ciab444","volume":"73","author":"KM Erlandson","year":"2021","unstructured":"Erlandson KM, Carter CC, Melbourne K, Brown TT, Cohen C, Das M, et al. Weight change following antiretroviral therapy switch in people with viral suppression: pooled data from randomized clinical trials. Clin Infect Dis. 2021;73:1440\u201351.","journal-title":"Clin Infect Dis"},{"key":"11334_CR2","doi-asserted-by":"publisher","first-page":"101412","DOI":"10.1016\/j.eclinm.2022.101412","volume":"48","author":"S Kanters","year":"2022","unstructured":"Kanters S, Renaud F, Rangaraj A, Zhang K, Limbrick-Oldfield E, Hughes M, et al. Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy - a systematic literature review and network meta-analysis. EClinicalMedicine. 2022;48:101412.","journal-title":"EClinicalMedicine"},{"key":"11334_CR3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1056\/NEJMoa1902824","volume":"381","author":"WDF Venter","year":"2019","unstructured":"Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, et al. Dolutegravir plus two different prodrugs of Tenofovir to treat HIV. N Engl J Med. 2019;381:803\u201315.","journal-title":"N Engl J Med"},{"issue":"6","key":"11334_CR4","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/cid\/ciz999","volume":"71","author":"PE Sax","year":"2020","unstructured":"Sax PE, Erlandson KM, Lake JE, Mccomsey GA, Orkin C, Esser S, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71(6):1379\u201389. https:\/\/doi.org\/10.1093\/cid\/ciz999.","journal-title":"Clin Infect Dis"},{"key":"11334_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12916-016-0588-4","volume":"14","author":"CA Sabin","year":"2016","unstructured":"Sabin CA, Reiss P, Ryom L, Phillips AN, Weber R, Law M, et al. Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. BMC Med. 2016;14:61.","journal-title":"BMC Med"},{"key":"11334_CR6","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1086\/649897","volume":"201","author":"SW Worm","year":"2010","unstructured":"Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010;201:318\u201330.","journal-title":"J Infect Dis"},{"key":"11334_CR7","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","volume":"371","author":"CA Sabin","year":"2008","unstructured":"D:A:D Study Group, Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371:1417\u201326.","journal-title":"Lancet"},{"key":"11334_CR8","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1097\/QAD.0b013e328347fa16","volume":"25","author":"AI Choi","year":"2011","unstructured":"Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, Shlipak MG. Cardiovascular risks associated with abacavir and Tenofovir exposure in HIV-infected persons. AIDS. 2011;25:1289\u201398.","journal-title":"AIDS"},{"key":"11334_CR9","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/cid\/civ316","volume":"61","author":"M Desai","year":"2015","unstructured":"Desai M, Joyce V, Bendavid E, Olshen RA, Hlatky M, Chow A, et al. Risk of cardiovascular events associated with current exposure to HIV antiretroviral therapies in a US veteran population. Clin Infect Dis. 2015;61:445\u201352.","journal-title":"Clin Infect Dis"},{"key":"11334_CR10","doi-asserted-by":"publisher","first-page":"e075673","DOI":"10.1136\/bmjopen-2023-075673","volume":"13","author":"KBH Pedersen","year":"2023","unstructured":"Pedersen KBH, Knudsen A, M\u00f8ller S, Siebner HR, Hove JD, Gerstoft J, et al. Changes in weight, body composition and metabolic parameters after switch to dolutegravir\/lamivudine compared with continued treatment with dolutegravir\/abacavir\/lamivudine for virologically suppressed HIV infection (The AVERTAS trial): a randomised, open-label, superiority trial in copenhagen, Denmark. BMJ Open. 2023;13:e075673.","journal-title":"BMJ Open"},{"key":"11334_CR11","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.jclinepi.2010.02.005","volume":"63","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010;63:834\u201340.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"11334_CR12","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/cid\/ciae191","volume":"79","author":"DA Wohl","year":"2024","unstructured":"Wohl DA, Koethe JR, Sax PE, McComsey GA, Kuritzkes DR, Moyle G, et al. Antiretrovirals and weight change: weighing the evidence. Clin Infect Dis. 2024;79(4):999\u20131005. https:\/\/doi.org\/10.1093\/cid\/ciae191.","journal-title":"Clin Infect Dis."},{"key":"11334_CR13","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1007\/s00125-012-2639-5","volume":"55","author":"BM Kaess","year":"2012","unstructured":"Kaess BM, Pedley A, Massaro JM, Murabito J, Hoffmann U, Fox CS. The ratio of visceral to subcutaneous fat, a metric of body fat distribution, is a unique correlate of cardiometabolic risk. Diabetologia. 2012;55:2622\u201330.","journal-title":"Diabetologia"},{"key":"11334_CR14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41572-020-0181-1","volume":"6","author":"JR Koethe","year":"2020","unstructured":"Koethe JR, Lagathu C, Lake JE, Domingo P, Calmy A, Falutz J, et al. HIV and antiretroviral therapy-related fat alterations. Nat Rev Dis Primers. 2020;6:48.","journal-title":"Nat Rev Dis Primers"},{"key":"11334_CR15","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/QAD.0000000000002119","volume":"33","author":"M Gelpi","year":"2019","unstructured":"Gelpi M, Afzal S, Fuchs A, Lundgren J, Knudsen AD, Drivsholm N, et al. Prior exposure to thymidine analogs and didanosine is associated with long-lasting alterations in adipose tissue distribution and cardiovascular risk factors. AIDS. 2019;33:675\u201383.","journal-title":"AIDS"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11334-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11334-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11334-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T05:16:57Z","timestamp":1757481417000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11334-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11334"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11334-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2025,9,3]]},"assertion":[{"value":"18 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the Capital Region, Denmark and the Danish Medicines Agency and Regional Data Protection Centre, Denmark. Informed consent was obtained from all study participants. The study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1100"}}